Successful use of methylprednisolone for treating severe COVID-19 - 05/08/20
Doi : 10.1016/j.jaci.2020.05.021
Jing Liu, MD, PhD a, b, ∗, Xiaobin Zheng, MD, PhD a, ∗, Yiying Huang, MD, PhD a, Hong Shan, MD, PhD b, c 
, Jin Huang, MD, PhD a, b
, Jin Huang, MD, PhD a, b a Department of Pulmonary and Critical Care Medicine, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China
b Guangdong Provincial Key Laboratory of Biomedical Imaging and Guangdong Provincial Engineering Research Center of Molecular Imaging, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China
c Department of Radiology, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.
Si connetta per beneficiarne
| This work was supported by grants from Natural Science Foundation of Guangdong Province of China (Grant No. 2020A1515011147 to J.L.) and Scientific Research Foundation of Guangdong Province (Grant No. A2020176 to X.Z.). |
|
| Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest. |
© 2020
American Academy of Allergy, Asthma & Immunology. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Vol 146 - N° 2
P. 325-327 - Agosto 2020 Ritorno al numero
Articolo precedente
- Expression of SARS-CoV-2 receptor ACE2 and coincident host response signature varies by asthma inflammatory phenotype
- Matthew Camiolo, Marc Gauthier, Naftali Kaminski, Anuradha Ray, Sally E. Wenzel
- Association of asthma and its genetic predisposition with the risk of severe COVID-19
- Zhaozhong Zhu, Kohei Hasegawa, Baoshan Ma, Michimasa Fujiogi, Carlos A. Camargo, Liming Liang
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.